Yang Rui has never made a new drug in its entirety, so it takes too time and is unnecessary.

Few pharmaceutical companies in the world will make a new drug from beginning to end and sell it. For the same reason - a 20-year-old drug company cannot stand it. If a century-old store or a two-hundred-year-old company spends all its time on drug development, it will only be able to make a few in its lifetime, and it has to be wary of about 6/7 of the chance of failure...

Even super pharmaceutical companies have their own focus, such as the most famous Pfizer, whose strongest ability is sales. Of course, this does not mean that their manufacturing and R&D capabilities are weak, such as Sildenafil, the main ingredient of Viagra, was developed by Pfizer's branch.

Historically, it took them almost six or seven years to find a suitable active compound, and then it was verified for five or six years, perfectly proving that sildenafil has no use in lowering blood pressure...

As for developing it into Viagra, it is better to say that it is not so lucky to be a desperate fight!

For Pfizer, if a failure in developing a new drug is inevitable, there will be no new drug announced to fail in that year.

But, for researchers who devoted themselves to this, how many decades have they lived?

For the researcher in charge of the project, the cost of investment is even higher. He has to spend at least ten years to accumulate experience. Maybe fifteen to twenty years before he has the opportunity to host such a project. This is not considered previous academic investment. If a new drug failed, especially the first new drug he hosted in his life, the result will be disastrous.

Being the head of a laboratory is like being a director of a video.

Investors allow you to fail. You can bear some losses in the short term or even a small loss in the long term. Just like a film that invests 10 million yuan, the box office of 10 million is not completely unacceptable. The director who made such a film will not be sought after or even welcome, but can still find a job.

However, if the investment of a new drug research and development of $30 million and the "box office" results are zero, what do investors think?

Can the researcher in charge of this project find new projects?

Of course, there are still relatively few cases of complete losses in the development of new drugs.

Especially if you look at the time span a little more, developing new compounds is the lowest risk - compared to the entire process of new drug development.

It is also because of this that Yang Rui started with compounds in the first place.

It has the lowest requirements for laboratories and the least requirements for researchers. The most important thing is that as long as the cost is controlled, even the worst compounds can be sold for money.

In other words, there are no bad compounds, only medical experts who cannot find their uses. For example, the Sangong Pharmaceutical Team led by Endo Akira was first found by the Japanese Akira Endo. It took more than two years to screen more than 6,000 different microorganisms to find the compound, and then it took another 7 years to conduct clinical trials.

However, the Japanese stopped clinical trials around 80 years ago, because the canines that performed animal experiments showed an unsettling increase in the proportion of malignant tumors.

Merck Pharmaceutical, which screened out similar compounds in 1978, originally wanted to get a cheap one, but unexpectedly, this happened just after spending a huge amount of money to make the compounds. In order not to let the previous investment go to waste, he had to continue the clinical trials anxiously. Finally, he was lucky enough to start the sales path of the 10 billion-level blockbuster Lovastatin.

Therefore, although the chance of compounds being cheated is great, they can still be sold for money.

Buying and selling compounds is also very common in the pharmaceutical industry.

The milestone of the deferrotonide compound made by Yang Rui has now earned hundreds of millions of dollars. Although the new drug for Gaucher's disease was handed over to Northern Pharmaceuticals, Yang Rui started well, so foreign companies such as Jielikang were willing to use money to participate.

The compounds of sildenafil were not expensive or cheap before 92 years.

Pfizer is still looking forward to it at present: If a drug that lowers blood pressure is effective, it is a bombshell. If it sells $1 billion a year, the profit will be at least hundreds of millions of dollars.

It is also for such expectations that Pfizer can tolerate tens of millions of dollars in annual expenses.

However, by around 1992, when it was proved that sildenafil was clinically ineffective, its value plummeted.

However, Yang Rui is not qualified to go to the card time.

Even useless compounds will become expensive when they fall into Pfizer's hands, which is well known to everyone in the market.

If they dragged it around and found something strange, Yang Rui would not be able to intercept it.

Therefore, Yang Rui made a decision and sent two employees from Huarui Company to contact Pfizer.

At the same time, Yang Rui also released the news, saying that Huarui Company was preparing to further develop pharmaceutical R&D capabilities...

Comrade Li Zhangzhen from Huarui Company was very happy about this.

As the head of the company, the larger the company and the more projects the company has, the stronger the sense of accomplishment.

Compared to simply doing pharmaceutical sales, it sounds much more handsome, such as production, education and research.

Comrade Li Zhangzhen's happiness lasted for about a week.

In a blink of an eye, his excitement disappeared from his eyes. When he met Yang Rui, he was even more depressed: "Pfizer refused."

"Oh, what's the reason?" Yang Rui was not surprised.

"There is no useful reason. They don't want to sell sildenafil yet." Li Zhang said with regret in his words and asked again: "Do you have any other goals?"

"Pfizer refused so directly?" Yang Rui cared more about Li Zhangzhen's attitude. He obviously gave up completely.

Li Zhangzhen nodded helplessly and said, "Pfizer said that since it is the Nobel Prize winner Mr. Yang Rui is optimistic about the compounds, they will at least increase their investment to try them."

"Uh..." Yang Rui thought of this possibility, but it was a bit embarrassing to be told directly by someone.

"The safety test of sildenafil is very good, and Pfizer still has some fantasies about it." Li Zhangzhen sighed.

Yang Rui said disrespectfully: "Anti-hypertensive drugs are common medicines, and patients have to take them every day. There is a lot of competition in the market and poor safety, so there is no value for development."

"But it's not easy to find a compound with good safety." Li Zhangzhen said regretfully: "Pfizer did not mention the price, so he should have no interest at all."

"Yeah..." Yang Rui pondered slightly.

"Actually, I learned that there are many good antihypertensive compounds on the market. If you buy them from small companies, it may be easier..."

"Since it's not a price issue, let's look for a breakthrough from another perspective." Yang Rui didn't take Li Zhangzhen's stubbornness and said to himself: "If you ask them to consult Pfizer, just say... let the market change technology."

"Market? What market?" Li Zhangzhen was still a little unconscious.

"Of course it's the Chinese market." Yang Rui said with the attitude of the GMP committee leader: "You just tell them that if they don't want to talk to us, there will be no need to talk about Pfizer's new drugs if they want to enter the Chinese market in the future."

There should be BGM here!
Chapter completed!